Summary.-The murine dose of i.v. C. parvum (466 tLg) was compared with a single, low, human-equivalent dose of 70 ,ug and with repeated weekly low doses. All treatments increased the antibody titre against C. parvum (CP). However, repeated doses stimulated a much higher titre than single doses. In all treated animals spleen weight peaked at 2 weeks and then fell. A single low dose caused a 3-fold increase, a single high dose or multiple low doses a 6-fold increase. Liver weight changes followed a similar pattern. Hepatosplenomegaly was prolonged by multiple doses.
SYSTEMICALLY INJECTED C. parvum (CP) has considerable anti-tumour properties in rodents (Halpern et al., 1966; Woodruff & Boak, 1966; Smith & Scott, 1972; Proctor et al., 1973; Sadler & Castro, 1976) . It is a potent stimulant of the reticulo-endothelial system (RES) (Halpern et al., 1963; Adlam & Scott, 1973) and non-specific activation of macrophages is generally regarded as mediating the anti-tumour effect (reviewed by Milas & Scott, 1978) . Cancer patients have been treated with systemic CP (Israel et al., 1975; Takita & Moayeri, 1976; Sarna et al., 1977) but there is still no convincing evidence of a beneficial antitumour response. This difference between man and rodents may be due to the dose of the vaccine since, owing to the severity of the side-effects, the human dose, when related to surface area, is much lower than the murine dose (Scott & Warner, 1976) .
The aim of this study was to determine, in mice, the best treatment regimen for cancer using CP. We compared our usual mouse dose (a single injection of 466 /tg) with a single low, human-equivalent dose (70 jig) and with repeated humanequivalent doses.
MATERIALS AND METHODS
Mice.-Age-matched syngeneic female C57BL mice (Olac) were used. C. parvum.-A heat-killed suspension of C. parvum (Wellcome, strain CN6134, 7 mg dry weight/ml) was used. The high dose was 466 jLg and the low or human-equivalent dose was 70 ,ug. This was calculated from our clinical dose of 10 mg/M2 (Mitcheson & Castro, 1978) relating the surface area of a 20g mouse to a 70kg human. Repeated treatments were given weekly. The (Sugiura & Stock, 1955) was implanted s.c. as a 0Iml homogenate in the lower flank. It is a rapidly growing epidermoid carcinoma which, when implanted s.c., metastasizes to the lungs (SimpsonHerren et al., 1974) . Cells are released from the primary tumour 6 days after implantation (James & Salsbury, 1974) and macroscopic metastases are easily visible 21 days after implantation.
Anti-tumour effects.-Two experimental systems were used. In the first the tumour was inoculated s.c. on Day 0 and the growth of the primary tumour monitored by measuring 2 diameters twice weekly and calculating the mean diameter. The mice were killed on Day 21 and macroscopic lung metastases counted after staining the lungs by inflation with Indian ink (Wexler, 1966) . In the second the tumour was implanted on Day 0 and subsequently excised on Day 10 (Sadler & Castro, 1976) . The survival of the mice after tumour excision was noted.
Statistics-Results were compared using Student's t test. Group survival was expressed as the harmonic mean survival time.
RESULTS

Biological effects
Toxicity.-Mice given a high dose of CP became very ill for several hours with erect fur, dyspnoea and a slow, staggering gait. The low dose had little adverse effect. All mice had a decrease in body weight which lasted 2-3 weeks and this was greater in mice receiving the larger dose.
Antibody titre.-Antibody titres expressed as the power of 2 are shown in Fig. 1 is shown in Fig. 2 . In all treated mice, spleen weight peaked at 2 weeks and then fell. A single low dose caused a 3-fold increase in spleen weight. A single high dose or multiple low doses caused a 6-fold increase. This splenomegaly was prolonged by multiple doses. Liver weight is shown in Fig. 3 and the changes follow a similar pattern to that of the spleen. Thymus weight is shown in Fig. 4 . Cortical atrophy of the thymus occurred and followed an inverse pattern to the alterations of spleen and liver weights. Single-dose prophylaxis.-CP was given at intervals up to 3 weeks before the tumour (Table IV) . Treatment one week before tumour significantly inhibited primary tumour growth and significantly reduced the number of pulmonary metastases and was as effective as treatment on the day of tumour implantation. Earlier pre-treatment did not inhibit primary tumour growth, though the number of pulmonary metastases was significantly reduced by treatment 2 weeks before tumour. Treatment 3 weeks before tumour was ineffective.
Combination of low-dose prophylaxis with a further dose at tumour inoculation.-Repeated low-dose prophylaxis was combined with an additional low dose on Day 0 (Table V) 18 24-8+ 2-0 prophylaxis, the first group on Days -21, -14 and -7, the second on Days -14 and -7 and the third on Day -7. A separate group received CP only on Day 0. The growth of the primary tumour was similar in all groups. The number of pulmonary metastases was significantly reduced in mice receiving CP only on Day 0. However, in mice which received prophylaxis and CP on Day 0 there was no inhibition of metastases.
Low-dose prophylaxis followed by a 13-week treatment-free interval.-The preceding experiment was repeated leaving a 13-week treatment-free interval between prophylaxis and tumour implantation (Table VI) . A similar result occurred; the Scott, 1974a) . The human dose is much lower, 2-10 mg/M2 (Thatcher & Crowther, 1978; CederholmWilliams et al., 1978; Mitcheson & Castro, 1978) In C57/BL mice a single high dose caused considerable toxic side-effects, including thrombosis (Lampert et al., 1977) . A second high dose caused an anaphylactic-type reaction and death (Mitcheson, in preparation) . Low doses were much better tolerated, and could be repeated. Both high and low doses caused hepatosplenomegaly, but thrombosis and subsequent infarction and necrosis were much less severe in animals receiving a low dose. Interestingly, repeated doses did not cause fresh pathology.
CP's antitumour action is attributed to non-specific activation of macrophages (reviewed in Milas & Scott, 1978) . RES stimulation can be measured by weight increases of liver and spleen or by stimulation of phagocytic activity, and these can be used as indices of anti-tumour activity (Adlam & Scott, 1973; McBride et al., 1975) . On this basis we predicted that repeated low doses would give the best anti-tumour effect, but this was not supported by our subsequent findings. Fisher et al. (1975) found that repeated i.p. injections of a therapeutic dose of CP inhibited primary tumour growth more than a single injection and Milas et al. (197.5) reported that the antitumour protection afforded by repeated suboptimal doses of CP in mice was greater than that of the total dose given as a single i.v. injection.
CP administered up to 2 weeks before tumour implantation inhibited pulmonary metastasis as effectively as treatment on the day of tumour implantation. Pretreatment earlier than 2 weeks was ineffective. However, when repeated lowdose prophylaxis was combined with a therapeutic low dose on the day of tumour implantation, the anti-metastatic action was completely neutralized. A similar finding has been reported after repeated prophylaxis with C. granulo8um (Milas et al., 1975) . In contrast, Scott & Warner (1976) found resistance to tumour-cell challenge in mice that had received 14 weekly prophylactic injections of a "human-equivalent" dose of CP (5.25 mg/M2). There are several mechanisms by which the anti-metastatic action of CP could be neutralized:
(1) The RES stimulated by CP may become refractory to further stimulation. This is suggested by the impaired development of hepatosplenomegaly in mice which received a second injection of CP 2 weeks after the first and would explain why repeated low doses did not maintain maximum hepatosplenomegaly. However, this "refractory period" lasts less than 4 weeks after a single injection and neutralization of the anti-metastatic effect still occurred after a 13-week treatment-free interval.
(2) Circulating immune complexes (CIC) can block cell-mediated immunity (Baldwin & Robins, 1976 ) and large quantities can saturate the RES (Mannik et al., 1974) . We have found that repeated doses of CP caused a significant and prolonged increase in CIC in mice (Mitcheson, in preparation) .
(3) The high titre of anti-CP antibody produced after repeated doses, or indeed, the injected CP itself, may in some way neutralize the anti-metastatic effect.
(4) CP may promote suppressor-cell activity (Mathe et al., 1978) .
Repeated human-equivalent doses of CP in mice have less adverse side-effects and cause most RES change. They raise very high antibody titres and increase circulating immune complexes. However, their anti-tumour effect is no greater than that of a single "human-equivalent" dose and, indeed, repeated prophylaxis neutralizes the protective action. We conclude that in our mouse system the best cancer treatment with CP is a single human-equivalent dose (70 pg) administered i.v. This finding may have clinical implications for C. parvum therapy.
